Cellenkos' CK0804 Receives Orphan Drug Designation for Myelofibrosis Treatment Cellenkos recently received Orphan Drug Designation from the FDA for CK0804, a novel therapy aimed at treating myelofibrosis, a rare blood cancer affecting thousands.

Cellenkos' CK0804 Receives Orphan Drug Designation for Myelofibrosis Treatment #USA #Houston #Myelofibrosis #Cellenkos #CK0804

New Findings on CK0804 Therapy Show Promise for Treating Myelofibrosis Patients Recent data reveal that Cellenkos' CK0804 therapy significantly reduces spleen volume and transfusion needs in myelofibrosis patients resistant to traditional treatments.

New Findings on CK0804 Therapy Show Promise for Treating Myelofibrosis Patients #USA #Orlando #Myelofibrosis #Cellenkos #CK0804